CLINICAL TRIALS AND OBSERVATIONS A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia
نویسندگان
چکیده
1Yale University School of Medicine and Yale Cancer Center, New Haven, CT; 2Texas Children’s Cancer Center, Houston, and National Institute of Mental Health, Rockville, MD; 3University of Washington School of Medicine, Seattle; 4David Geffen School of Medicine at University of California, Los Angeles; 5Yale Center for Clinical Investigation, New Haven, CT; 6Children’s Oncology Group Operations Center, Arcadia, CA; 7Oregon Health & Science University, Portland; 8Children’s Hospitals and Clinics, Minneapolis, MN; and 9University of Minnesota Medical School, Minneapolis
منابع مشابه
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01
The Dana-Farber Cancer Institute (DFCI) acute lymphoblastic leukemia (ALL) Consortium Protocol 91-01 was designed to improve the outcome of children with newly diagnosed ALL while minimizing toxicity. Compared with prior protocols, post-remission therapy was intensified by substituting dexamethasone for prednisone and prolonging the asparaginase intensification from 20 to 30 weeks. Between 1991...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Comparison of Escherichia coli–asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer—Children’s Leukemia Group phase 3 trial
Asparaginase is an enzyme used in the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in children. It has minimal bone marrow toxicity. Its major side effects are anaphylaxis, pancreatitis, diabetes, coagulation abnormalities, and thrombosis, especially intracranial. It is derived from 2 different sources: Escherichia coli and Erwinia chrysanthemi. Nonrandomized clinical st...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia
We have previously hypothesized that higher systemic exposure to asparaginase may cause increased exposure to dexamethasone, both critical chemotherapeutic agents for acute lymphoblastic leukemia. Whether interpatient pharmacokinetic differences in dexamethasone contribute to relapse risk has never been studied. The impact of plasma clearance of dexamethasone and anti–asparaginase antibody leve...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial
The pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant Escherichia coli–asparaginase preparation was compared with Asparaginase medac. Thirty-two children with acute lymphoblastic leukemia were randomized to receive one of both agents at a dose of 5000 U/m2 every 3 days, for a total of 8 doses during induction treatment. The serum activity-time profile after the first...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Acute mixed lineage leukemia in children: the experience of St Jude Children’s Research Hospital
To characterize the biology and optimal therapy of acute mixed-lineage leukemia in children, we reviewed the pathologic and clinical features, including response to therapy, of 35 patients with mixedlineage leukemia. The majority of cases (91%) had blasts cells that simultaneously expressed either T-lineage plus myeloid markers (T/myeloid, n 20) or B-lineage plus myeloid markers (B/myeloid, n 1...
متن کامل